



## Briefing Materials

### Session 1:

- Ballantyne CM, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. *Atherosclerosis*. October 2018. <https://pubmed.ncbi.nlm.nih.gov/29910030/>
- Ballantyne CM, Laufs U, Ray KK, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. *Eur J Prev Cardiol*. April 2020. <https://pubmed.ncbi.nlm.nih.gov/31357887/>
- Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial. *JAMA*. November 12, 2019. <https://pubmed.ncbi.nlm.nih.gov/31714986/>
- Laufs U, Banach M, Mancini GBJ, et al. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance. *J Am Heart Assoc*. April 2, 2019. <https://pubmed.ncbi.nlm.nih.gov/30922146/>
- Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. *N Engl J Med*. April 16, 2020. <https://pubmed.ncbi.nlm.nih.gov/32197277/>
- Ray KK, Bays HE, Catapano AL, et al. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. *N Engl J Med*. March 14, 2019. <https://pubmed.ncbi.nlm.nih.gov/30865796/>
- Ray KK, Landmesser U, Leiter L, et al. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. *N Engl J Med*. 2017. <https://www.nejm.org/doi/full/10.1056/NEJMoa1615758>
- Ray KK, Wright RS, Kallend D, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. *N Engl J Med*. April 16, 2020. <https://pubmed.ncbi.nlm.nih.gov/32187462/>

### Session 2:

- Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. [Section 5: Statin Safety and Statin Associated Side Effects]. *J Am Coll Cardiol*. June 25, 2019. <https://pubmed.ncbi.nlm.nih.gov/30423391/>
- Keating AJ, Campbell KB, Guyton JR. Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy. *Ann Pharmacother*. March 2013. <https://pubmed.ncbi.nlm.nih.gov/23482733/>



- Laufs U, Banach M, Mancini GBJ, et al. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance. *J Am Heart Assoc.* April 2, 2019. <https://pubmed.ncbi.nlm.nih.gov/30922146/>
- Mampuya WM, Frid D, Rocco M, et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. *Am Heart J.* September 2013. <https://pubmed.ncbi.nlm.nih.gov/24016512/>
- Rosenson RS, Baker S, Banach M, et al. Optimizing Cholesterol Treatment in Patients With Muscle Complaints. *J Am Coll Cardiol.* September 5, 2017. <https://pubmed.ncbi.nlm.nih.gov/28859793/>
- Serban MC, Colantonio LD, Manthripragada AD, et al. Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction. *J Am Coll Cardiol.* March 21, 2017. <https://pubmed.ncbi.nlm.nih.gov/28302290/>
- Virani SS, Akeroyd JM, Ahmed ST, et al. The use of structured data elements to identify ASCVD patients with statin-associated side effects: Insights from the Department of Veterans Affairs. *J Clin Lipidol.* Sept-Oct 2019. <https://pubmed.ncbi.nlm.nih.gov/31501043/>